Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3 registrational study of NVG-291 marking a step towards what could become the first pharmacologic treatment for spinal cord injury the most significant clinical trial results 10 April 2026 has to offer from across the pipeline.
This week’s readouts covered autoimmune disease, psychiatry, and neurotrauma, offering a cross-section of the pipeline’s momentum and setbacks. Amgen’s delivery innovation success in thyroid eye disease contrasts sharply with Lipocine’s efficacy failure in postpartum depression, while NervGen’s regulatory milestone represents a moment of genuine hope for a patient population that has waited decades for a pharmacologic option. Here, Life Science Daily News brings you the most significant clinical trial results 10 April 2026.
Amgen’s Subcutaneous Tepezza Meets Phase 3 Primary Endpoint in Thyroid Eye Disease
Amgen announced on 6 April 2026 positive topline results from the Phase 3 TEPEZZA OBI trial, evaluating teprotumumab-trbw (Tepezza) administered via subcutaneous injection using an on-body injector in participants with moderate-to-severe active Thyroid Eye Disease (TED).
The trial met its primary endpoint with a statistically significant and clinically meaningful proptosis response rate of 76.7% in the treatment arm compared with 19.6% in the placebo arm at week 24 (p<0.0001). The mean proptosis reduction, a key secondary endpoint, was 3.17 mm for the Tepezza OBI group compared with 0.80 mm for placebo — a difference widely considered clinically meaningful in TED. Multiple secondary endpoints also achieved statistical significance, including overall responder rate, diplopia response rates, and patient-reported appearance scores.
The Phase 3 TEPEZZA OBI trial (ClinicalTrials.gov identifier: NCT06248619) was a randomised, double-masked, placebo-controlled, parallel-group, multi-centre study. Participants received either subcutaneous Tepezza or placebo via an on-body injector every two weeks for a total of 12 injections. The safety profile was broadly consistent with the established profile of intravenous Tepezza, with mild-to-moderate injection site reactions observed but not resulting in treatment discontinuation. The most commonly reported adverse events were muscle spasms, tinnitus, weight decrease, ear discomfort, nausea, and diarrhoea.
Tepezza is currently the first and only approved medicine for TED and has been administered intravenously to more than 25,000 patients worldwide. A subcutaneous formulation would represent a meaningful advance in administration convenience, potentially supporting broader access and greater patient adherence. Amgen plans to present the complete data at a forthcoming medical congress and to discuss the results with global regulatory authorities with a view to filing.
Lipocine’s Oral Brexanolone Phase 3 Trial Fails to Meet Primary Endpoint in Postpartum Depression
This story broke on 2 April and was not included in last week’s roundup. Given its clinical significance, we are covering it here.
Lipocine announced on 2 April 2026 that its Phase 3 placebo-controlled trial of LPCN 1154 — an oral formulation of brexanolone — failed to meet the primary endpoint for the treatment of postpartum depression (PPD). Shares fell approximately 78% on the news, reflecting the severity of the setback for the programme.
Brexanolone is a synthetic form of allopregnanolone, a neurosteroid that modulates GABA-A receptors and plays a key role in the hormonal shifts that occur around childbirth. It is already approved by the FDA in intravenous form under the brand name Zulresso, manufactured by Sage Therapeutics, but the current label requires a 60-hour continuous intravenous infusion in a certified healthcare setting — a significant access barrier. An oral formulation, if successful, could have substantially expanded the addressable population by enabling home-based treatment.
The failure of LPCN 1154 is a notable setback not only for Lipocine but for broader efforts to make neurosteroid-based PPD treatments more accessible. The postpartum depression space has seen growing clinical attention in recent years, driven by the commercial success of Zulresso and the subsequent FDA approval of zuranolone (Zurzuvae) — an oral neurosteroid approved in 2023 with a 14-day daily dosing course. The outcome of Lipocine’s trial is a reminder that oral reformulation of an established molecule does not automatically translate to equivalent efficacy, and that pharmacokinetic optimisation for neurosteroid delivery remains a significant challenge. Lipocine has not yet disclosed whether it intends to pursue further development of the programme.
NervGen Secures FDA Alignment on RESTORE Phase 3 Registrational Study for Chronic Tetraplegia
NervGen Pharma announced on 7 April 2026 the successful completion of an End-of-Phase 2 meeting with the FDA and full alignment on RESTORE, the company’s Phase 3 registrational study evaluating NVG-291 for the treatment of chronic tetraplegia. There are currently no approved pharmacologic treatments for spinal cord injury, making this a landmark regulatory milestone for a patient population that has long lacked options beyond rehabilitation.
NVG-291 is a subcutaneously administered neuroreparative peptide targeting the inhibitory CSPG-PTPσ pathway, designed to promote nervous system repair rather than manage symptoms. The drug received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency. Its Phase 1b/2a CONNECT SCI study in chronic tetraplegia demonstrated improvements in function, independence, and quality of life, providing the clinical foundation for the RESTORE design.
RESTORE is a 16-week, randomised, double-blind, placebo-controlled registrational study that will enroll approximately 150 adults aged 18 to 75 with chronic tetraplegia due to traumatic spinal cord injury (C7 or above, ASIA Impairment Scale C or D; one to ten years post-injury) across up to 60 sites in the United States and Canada. Participants will receive daily subcutaneous injections of NVG-291 for 12 weeks followed by a four-week observational period. The primary endpoint is change from baseline in GRASSP Quantitative Prehension at week 12, a validated functional measure of fine-motor hand use — identified as the highest priority domain for people living with tetraplegia. Key secondary endpoints include Patient and Clinician Global Impression of Change, the Spinal Cord Independence Measure Version III, and lower extremity spasticity. An optional 12-week open-label extension will follow, providing NVG-291 access to all placebo randomised participants.
NervGen has elected to conclude enrolment in the Phase 1b/2a CONNECT SCI subacute tetraplegia cohort following the RESTORE alignment, and will apply the regulatory framework and endpoint approach agreed with the FDA to inform future registrational work in the subacute population. Study initiation for RESTORE remains on track for mid-2026.
Looking Ahead
This week’s clinical trial results 10 April 2026 reflect a pipeline characterised by meaningful contrasts: a significant delivery innovation success, a sobering reformulation failure, and a long-awaited regulatory green light in one of medicine’s most challenging areas. Amgen’s subcutaneous Tepezza data could reshape how thyroid eye disease is managed for tens of thousands of patients globally. Lipocine’s setback is a timely reminder that translating an established mechanism into a new delivery format demands rigorous pharmacokinetic validation. And NervGen’s FDA alignment on the RESTORE trial brings the prospect of the first-ever pharmacologic treatment for spinal cord injury closer to reality, a development that matters profoundly to the estimated 5.4 million people living with SCI in the United States alone. Life Science Daily News will continue to bring you accurate, timely coverage of the clinical trial results 10 April 2026 that matter most across the global life sciences pipeline.
